Compare PPG Industries, Inc. (PPG) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PPG Industries, Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? PPG Industries, Inc. trades at $104.87 (market cap $23.31B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: PPG Industries, Inc. is far larger — about 4.6× Travere Therapeutics Inc. Common Stock's market cap, and PPG Industries, Inc. pays a 2.82% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold PPG Industries, Inc. for 68 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| PPG | TVTX | |
|---|---|---|
Market Cap | $23.31B | $5.02B |
Volume | 1,812,724 | 2,060,842 |
Sector | Basic Materials | Health |
52-Week High | $131.56 | $67.52 |
52-Week Low | $94.34 | $26.79 |
Typical Hold Time | 68 Days | 0 Days |
Enterprise Value | $29.18B | $5.15B |
Dividend Yield | 2.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPG Industries trades at $104.55, up 0.81% on the day, with a bearish technical signal from moving averages and oscillators. The company reported mixed Q2 2026 earnings, missing EPS estimates but showing 7% revenue growth. Fundamentals are solid with a P/E of 15, net income margin of 9.57%, and strong cash flow from operations of $1.94B in 2025. Recent news highlights innovation initiatives and leadership appointments aimed at driving growth.
The outlook is cautiously optimistic with a consensus price target of $130.50, implying 25% upside, supported by 55% analyst buy ratings. Key risks include margin pressures in the Automotive Refinish segment and macroeconomic headwinds in Europe. The stock offers value at current levels but requires monitoring of Q3 earnings on Oct 27 for confirmation of growth trajectory.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
